Preclinical studies have also identified several other potential targets for CAR-T cell therapy in myeloma, including CD44 splice variants [213], CD46 [214], CD56 [215], CD70 [216], CD74 [217], CD229 [218, 219], integrin β7 [220], Lewis Y antigen [221], ILT3 [222], SEMA4A [223], CCR10 [224], and Mucin 1 (MUC1) [225]. The gene discussed is MUC1; the disease is plasma cell myeloma.